No Prescription |
 |
 | ||
|
LERKA Zanidip |
|
| ||
No Prescription » Prescription Drugs 10 » LERKA Zanidip Lercanidipine Hydrochloride belongs to a group of medicines called calcium channel blockers which act on the heart and blood vessels. Lercanidipine slows the movement of calcium through cells which has two results. It decreases the rate at which the heart beats and also has a widening effect on blood vessels. This combination causes blood pressure to be reduced. What is it used for?High blood pressure (hypertension) Buy LERKA Zanidip and other Prescription Drugs 10 products online at Medstore. Buy Online at Medstore - Click Here!
About LERKA Zanidip: Product Type: Prescription Drugs 10 LERKA ( Zanidip Generic Lercanidipine ) LERKA (Zanidip Generic Lercanidipine) Zanidip Generic Lercanidipine 10 mg Tab Zanidip Generic Lercanidipine LERKA
View more Prescription Drugs 10 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
